My research project is focused on the development of an innovative anti-cancer modality, the Chimeric Antigen Receptor (CAR) therapy. This approach harnesses the potential of patients’ own immune cells to specifically kill their cancer. Practically, patients’ lymphocytes are modified with an innovative receptor (the CAR) to be redirected against a tumor antigen. The main goal of my project is to identify novel “targetable” antigens and develop innovative CAR designs to address the impediments of current CAR therapy especially against solid tumors.
Benjamin William Caulier
Postdoktor - Senter for kreftcelle-reprogrammering
Besøksadresse Ullernchausséen 70 0379 Oslo
Postadresse Postboks 4950 0424 Oslo
Publisert 7. apr. 2021 15:40 - Sist endret 7. okt. 2021 11:07